About Ouro Medicines
Ouro Medicines is a company based in San Francisco (United States) founded in 2024 was acquired by Gilead in March 2026. Ouro Medicines has raised $120 million across 1 funding round from investors including Gilead, UPMC and TPG. Ouro Medicines offers products and services including OM336 and T Cell Engagers. Ouro Medicines operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ouro Medicines
Ouro Medicines offers a comprehensive portfolio of products and services, including OM336 and T Cell Engagers.
Drug candidate for resetting immune systems in immune-mediated diseases
Modality for depleting proinflammatory cells to achieve immune reset
People of Ouro Medicines
Unlock access to complete
Unlock access to complete
Funding Insights of Ouro Medicines
Ouro Medicines has successfully raised a total of $120M through 1 strategic funding round. The most recent funding activity was a Series A round of $120 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ouro Medicines
Ouro Medicines has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, UPMC and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked |
Investor details for Ouro Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ouro Medicines
Investment portfolio details for Ouro Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ouro Medicines
Detailed financials for Ouro Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ouro Medicines Comparisons
Peer comparison for Ouro Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ouro Medicines
Ouro Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
Detailed competitors of Ouro Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ouro Medicines
Complete news archive for Ouro Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ouro Medicines
Ouro Medicines was founded in 2024 and raised its 1st funding round 1 year after it was founded.
Ouro Medicines is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Jaideep Dudani is the current CEO of Ouro Medicines.
Ouro Medicines is a funded company, having raised a total of $120M across 1 funding round to date.
Ouro Medicines was founded in 2024 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where therapeutics for chronic immune-mediated diseases are developed. Operations center on advancing treatments that target B cell biology. A lead candidate, OM336, is pursued for multiple myeloma and related immune conditions. The companys work supports patients through innovative therapeutic approaches in the immunology field.
Ouro Medicines's top competitors include Moderna, BeiGene and ADMA Biologics.
Ouro Medicines offers OM336 and T Cell Engagers.
Ouro Medicines has 9 investors. Key investors include Gilead, UPMC, TPG, Norwest Venture Partners, and GSK.